Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 1103 results for "fda"

FDA approves first pill to treat all forms of hepatitis C
FOXNews.com

FDA Approves First Pill to Treat All Forms of Hepatitis C

Federal health officials have approved the first pill to treat all major forms of hepatitis C, the latest in a series of drug approvals that have reshaped treatment of the liver-destroying virus. The Food and Drug Administration approved the ... ABC News, 1 hour ago
[x]  

2,894 images for fda

prnewswire.com, 15 minutes ago
Benzinga.com, 21 hours ago
bidnessetc.com, 23 hours ago
DailyNews724.com, 13 minutes ago
MassDevice, 5 hours ago
Xconomy, 18 hours ago
NDTV, 3 days ago
Food Engineering, 49 minutes ago
DailyNews724.com, 13 minutes ago
Nutraceuticals World, 14 hours ago

The FDA just approved a drug that treats all kinds of hepatitis C

The FDA just approved a new hepatitis C drug that works on all kinds of patients. The drug, Epclusa, is a combination of sofosbuvir (which was originally approved back in 2013) and velpatasvir (a new drug), both made by Gilead Sciences. Gilead ...
 Business Insider Australia1 hour ago
WorldNetDaily

FDA Ad Comm set for August 4 to review Egalet's NDA for abuse-deterrent opioid ARYMO ER

A joint meeting between the FDA's Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee will take place on August 4 to review Egalet's ( EGLT +2.9%) New Drug Application (NDA) seeking ...
 Seeking Alpha2 hours ago Egalet Announces FDA Advisory Committee Meeting will Take Place August 4, 2016 for Lead Abuse-Deterrent Candidate ARYMO ER (Morphine Sulfate) Extended-Release Tablets  Nasdaq3 hours ago Egalet Reveals FDA Advisory Committee Meeting For ARYMO ER Extended-Release Tablets  Benzinga.com48 minutes ago BRIEF-Egalet says FDA advisory committee meeting on August 4 for ARYMO  Reuters UK2 hours ago
[x]  

FDA approves Gilead's SOF/VEL for HCV

Under its Priority Review process, the FDA approves Gilead Sciences' ( GILD +3.2%) once-daily fixed-dose combination of sofosbuvir (SOF), a nucleotide analog polymerase inhibitor, and velpatasvir (VEL), a pan-genotypic NS5A inhibitor, for the ...
 Seeking Alpha2 hours ago
Bloomberg

Masimo Announces FDA 510k Clearance for Radius7 with rainbow Technology Including Continuous SpHb

Masimo Announces FDA 510(k) Clearance for Radius-7® with rainbow® Technology, Including Continuous SpHb® Tuesday, June 28, 2016 IRVINE, Calif.--( BUSINESS WIRE )-- Masimo (NASDAQ: MASI) announced today FDA 510(k) clearance for Radius-7 ® ...
 Asian Hospital & Healthcare Management54 minutes ago Masimo Announces FDA 510(k) Clearance for Radius-7® with rainbow® Technology, Including Continuous SpHb®  Business Wire5 hours ago Masimo : Announces FDA 510(k) Clearance for Radius-7® with rainbow® Technology, Including Continuous SpHb®  4 Traders4 hours ago
[x]  
Xconomy

Regulus Therapeutics Inc. (RGLS) Is Falling After FDA Puts RG-101 On Hold

Regulus Therapeutics Inc. (RGLS) announced after the bell Monday that it has received verbal notification from the FDA that RG-101 has been placed on clinical hold. The treatment for chronic hepatitis C virus infection was put on hold after Regulus ...
 RTTNews.com20 hours ago FDA places Regulus' IND for lead product candidate on clinical hold after second serious adverse event  Seeking Alpha20 hours ago FDA halts testing of Regulus' Hep C drug, sending shares into tailspin  BioPharma Dive44 minutes ago Regulus' shares slump as FDA places clinical hold on experimental hepatitis C drug RG-101  FirstWord Pharma8 hours ago
[x]  
BioSpace

FDA approves Epclusa for treatment of chronic Hepatitis C virus infection

/PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration approved Epclusa to treat adult patients with chronic hepatitis C virus (HCV) both with and without cirrhosis (advanced liver disease). For patients with moderate to severe cirrhosis ...
 BioSpace2 hours ago Gilead Release: FDA Approves Epclusa For Treatment Of Chronic Hepatitis C Virus Infection  BioSpace55 minutes ago BRIEF-FDA grants breakthrough therapy designation for Incytes Ruxolitinib  Reuters UK5 days ago Incyte Gets FDA Approval For Breakthrough Therapy Status For Its Ruxolitinib  Benzinga.com5 days ago
[x]  
Reuters

U.S. FDA approves Gilead's hep C drug Epclusa

June 28 (Reuters) - The U.S. Food and Drug Administration approved Gilead Sciences Inc's drug for treating chronic hepatitis C virus infection. The drug, Epclusa, is approved for use in combination with ribavirin. Epclusa is the first drug to ...
 Sharenet2 hours ago Read Comprehensive FDA Approved Drug List - 2012 (Medical Reference - FDA Approved Drugs) PDF  Dailymotion10 hours ago U.S. FDA approves Gileads hep C drug Epclusa  Reuters UK1 hour ago FDA approves Gilead's hep C drug Epclusa  Channel NewsAsia1 hour ago
[x]  
Nasdaq

Gilead's Epclusa approved by FDA for all six subtypes of hepatitis C virus

Gilead Scienceson Tuesdayannounced that the FDA approved Epclusa (sofosbuvir/velpatasvir), in combination with ribavirin, as the first all-oral, pan-genotypic, single-tablet treatment for adults with genotype 1-6 hepatitis C virus (HCV) infection.
 FirstWord Pharma48 minutes ago GILEAD SCIENCES : Gets FDA Approval for Combo Hepatitis C Drug  4 Traders1 hour ago Gilead Gets FDA Approval For Epclusa (Sofosbuvir/Velpatasvir) for All Genotypes Of Chronic Hepatitis C Treatment  Morningstar.com55 minutes ago Gilead Gets FDA Approval for Combo Hepatitis C Drug  Morningstar.com1 hour ago
[x]  

KITOV : 's Lead Drug KIT-302 Achieves Manufacturing Milestone Ahead of Planned NDA Filing with U.S. FDA

/PRNewswire/ -- Kitov Pharmaceuticals (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company focused on late-stage drug development, announced today that Dexcel Pharma , Kitov's manufacturing partner, has successfully completed an initial ...
 4 Traders2 hours ago Kitov's Lead Drug KIT-302 Achieves Manufacturing Milestone Ahead of Planned NDA Filing with U.S. FDA  PR Newswire2 hours ago Kitov''s Lead Drug KIT-302 Achieves Manufacturing Milestone Ahead of Planned NDA Filing with U.S. FDA  Nasdaq2 hours ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - fda
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less